Ophthalmology

In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Mamoru Ogawa, MD, noted that investigators have found that the choroidal and central corneal thicknesses increased over a very short period of time following intensive outdoor activity.

A poll for retina specialists regarding their attendance at the 2022 Retina World Congress in Fort Lauderdale, Florida. This poll is now closed.

Results from our recent poll regarding ARVO 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in Denver, Colorado.

According to the study, many patients with retinal vein occlusion maintain visual acuity gains above baseline at five years, but they require long-term monitoring and treatment.

A variety of surgical advances were presented at ASCRS; here is a brief overview for retina specialists.

Apellis Pharmaceuticals releases results of their Geographic Atrophy Insights Survey (GAINS), revealing a large emotional toll and significant decrease in independence for patients with geographic atrophy.

Over the past 2 years, retina specialists and their patients have learned how AI may be a tool physicians can use to monitor patients for disease progression, how telemedicine might mean more than a mere video chat between patient and clinician, and how the tools of the 21st century were closer to real-world practice than anticipated.

In patients with amblyopia, minuscule fixation eye movements play a major role with treatment, according to Fatema Ghasia, MD, associate professor of ophthalmology and director of the Vision Neuroscience and Ocular Motility Laboratory at the Cole Eye Institute at Cleveland Clinic in Ohio.

Impact of native lipids on rhodopsin signaling and regeneration opens door to GPCR drug discovery in native membrane environments.

A poll for retina specialists regarding their attendance at the Association for Research in Vision and Ophthalmology 2022 Meeting in Denver, Colorado. This poll is now closed.

Researchers at the University of Southern California have stimulated the retinas of blind mice using focused ultrasound technology.

Investigators reported that the incidence of retinal vein occlusions (RVOs) but not retinal artery occlusion, increased in the 6 months after COVID-19 diagnosis.

According to the company, post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints. The company plans to discuss findings with regulators in Q3.

An end-of-week review of retina news and stories from April 8-April 14.

According to review, patients with mild diabetic retinopathy at baseline fare better.

The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient, with the company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022.

According to researchers at the University of California, Irvine, base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis patients.

The trial will study the effect of the drug in treatment-naïve patients with diabetic macular edema (DME) who are members of underrepresented patient populations, ie, Black, Hispanic, Latin American, and Indigenous people.

The International Agency for the Prevention of Blindness (IAPB) recently announced an expansion of their ‘Focus on Glaucoma’ and ‘Focus on Diabetes’ series with their new ‘Focus on Child Eye Health’ series in partnership with CooperVision.

Investigators found that patients with neovascular age-related macular degeneration in all countries included in the study lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.

Approval is based on year 1 data from the Phase III KESTREL and KITE trials investigating brolucizumab 6 mg versus aflibercept 2 mg in DME patients.

A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells—a class of neurons located in the retina that are critical for vision.

Study focuses on ascertaining the risk of patients developing additional tumors

The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.

Horizon Therapeutics announces new data and a separate analysis will be presented at the American Academy of Neurology 2022 Annual Meeting, showing that UPLIZNA reduced disease activity associated with neuromyelitis optica spectrum disorder (NMOSD) over 3 years.

Bausch + Lomb and Clearside Biomedical Inc. are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis.

If the Biologics License Application is approved by the FDA, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.

A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.

Lower dose performs as effectively as a higher dose when treating ROP.

Suprachoroidal injections provide safe, effective drug delivery to target choroidal, retinal tissues.